Antibodies Archives

Screenshot 2017 01 09 at 12.40.51 PM e1483962109441

News and Trends 9 Jan 2017

German Immuno-Oncology Biotech partners up with Biotech Giant Amgen

Immatics and Amgen have inked a deal to develop bispecific drug candidates for cancer that could reach over €1B in milestones. Immatics, an immuno-oncology biotech in Tübingen, Germany, has signed an agreement with biotech giant Amgen. Immatics will receive €28.5M ($30M) upfront and up to €475M ($500M) per program and Amgen will be responsible for clinical development, manufacturing and […]

January 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Jan 2017

This British Biotech is buying its way into the Crowded NASH Space

Tiziana Life Sciences is acquiring candidates to gain leverage in the profitable NASH market, where there’s currently a fierce competition. Tiziana Life Sciences, a biopharmaceutical company from London, is planning to enter the competitive space of non-alcoholic steatohepatitis (NASH). To gain leverage over bigger companies fighting to enter a market expected to hit a massive €38B ($40B) by […]

January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 2 Jan 2017

The Story behind one of the Most Successful Danish Biotech Entrepreneurs

The series of profiles on impressive biotech leaders continues: John Haurum founded one of the most successful biotech companies in Denmark and is now leading one of the hottest European immuno-oncology companies. Here are some of his lessons and thoughts looking back at his rich career. John Haurum, born in Denmark, studied medicine at Aarhus University […]

January 2, 2017 - 6 minutesmins - By Philip Hemme

Best in Biotech 22 Dec 2016

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here’s a list of the best success stories of 2016. Biotech is becoming a powerful driving force in medicine, providing innovative therapies that could end some of the most severe diseases. To celebrate the advances in the area of […]

December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Dec 2016

Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments?

Hopes for an Alzheimer’s cure took a hit with Eli Lilly’s recent failure, but it’s not over yet. Probiodrug explains the failure and response. Alzheimer’s Disease devastates families and represents one of the largest financial burdens in society. Now the sixth leading cause of death for all age groups, the neurodegenerative disease cost the US […]

December 19, 2016 - 7 minutesmins - By Evelyn Warner

News and Trends 7 Dec 2016

Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies

Nordic Nanovector has bagged €55M to push its pipeline forward through the clinic. Investors seem to be attracted by its ARC and ADC programs, using some of the hottest antibody technologies to treat cancer. Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat non-Hodgkin lymphoma (NHL) and recently entered the trending antibody-drug conjugate (ADC) field to fight against leukemia. These […]

December 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Dec 2016

How is European Immuno-Oncology fighting Blood Cancer?

From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field. The 58th ASH annual meeting is wrapping up today, after the best companies […]

December 6, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

In Depth 29 Nov 2016

The ABCs of ADCs: A Review of Antibody Drug Conjugates

Antibody therapies have a little sister who is catching up in funding – and hype? In light of now five deaths from Juno’s CAR-T therapy, antibody drug conjugates are attracting a lot of interest in a resurgence after their debut 10 years ago. To feel out the field, we talked to two CEOs competing directly […]

November 29, 2016 - 8 minutesmins - By Evelyn Warner

News and Trends 25 Nov 2016

Stories We Didn’t Cover: Malaria Vaccine Money, Diabetes FDA Approvals

Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. WHO has injected €14M into GSK to advance its malaria vaccine. Umecrine Cognition, a […]

November 25, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 23 Nov 2016

These Biotech Veterans have Launched a Startup to ‘Drug the Undruggable’

GPCRs have spelled “dead end” for many a biotech and academic endeavor. I sat down with Confo Therapeutics to hear about how they’re recruiting antibodies for a new onslaught. Despite their allure as the key to many indications, GPCRs are not a target for the faint of heart because they tend to move through a […]

November 23, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 17 Nov 2016

Boehringer’s Biosimilar could take a Chunk out of the Cancer Market

Boehringer Ingelheim is getting ready to launch a biosimilar for Roche’s cancer blockbuster Avastin as soon as the patent expires. Can it overcome the fierce competition in a market expected to grow to 50% of the drug market by 2020? Boehringer Ingelheim just announced results from a Phase I trial showing that its biosimilar candidate […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

New Private Placement to Boost the Profitable Therapeutic Antibody Market

MorphoSys has announced a private placement of shares to raise funds for its antibody therapy programs. With this push, the company is solidifying its position as a leader in the therapeutic antibody market, which is expected to reach €117B by 2021. MorphoSys, one of the few European billion euro biotechs, develops therapeutic antibodies for immuno-oncology, inflammatory […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Antibodies

German Immuno-Oncology Biotech partners up with Biotech Giant Amgen

This British Biotech is buying its way into the Crowded NASH Space

The Story behind one of the Most Successful Danish Biotech Entrepreneurs

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments?

Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies

How is European Immuno-Oncology fighting Blood Cancer?

The ABCs of ADCs: A Review of Antibody Drug Conjugates

Stories We Didn’t Cover: Malaria Vaccine Money, Diabetes FDA Approvals

These Biotech Veterans have Launched a Startup to ‘Drug the Undruggable’

Boehringer’s Biosimilar could take a Chunk out of the Cancer Market

New Private Placement to Boost the Profitable Therapeutic Antibody Market

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!